JUMPCAN(SH:600566)2022-04-22 16:00Financial Performance - The company's operating revenue for Q1 2022 was RMB 2,173,660,458.16, representing a year-on-year increase of 13.43%[4] - Net profit attributable to shareholders was RMB 581,188,981.63, up 32.36% compared to the same period last year[4] - Basic earnings per share rose to RMB 0.654, reflecting a growth of 32.39% year-on-year[4] - The total operating revenue for the first quarter of 2022 was approximately CNY 2.17 billion, an increase from CNY 1.92 billion in the same period last year, representing a growth of about 13.4%[17] - The net profit for the first quarter of 2022 was approximately CNY 581.46 million, compared to CNY 439.10 million in the previous year, marking an increase of about 32.4%[19] - The basic earnings per share for the first quarter of 2022 was CNY 0.654, up from CNY 0.494 in the same quarter of the previous year, indicating a growth of approximately 32.4%[20] - The company achieved an operating profit of approximately CNY 610.47 million, up from CNY 494.89 million, reflecting a growth of about 23.3%[17] Cash Flow - The net cash flow from operating activities increased by 38.11% to RMB 1,006,008,812.50, driven by increased sales recovery[4] - Cash inflows from operating activities totaled approximately CNY 2.92 billion, compared to CNY 2.34 billion in the previous year, representing an increase of about 25.4%[21] - The cash outflows from operating activities were approximately CNY 1.92 billion, up from CNY 1.61 billion, reflecting an increase of about 19.3%[21] - The net cash flow from operating activities for Hubei Jichuan Pharmaceutical Co., Ltd. was 1,006,008,812.50 CNY in Q1 2022, compared to 728,435,343.48 CNY in the same period last year, indicating a significant increase[22] - The total cash flow for the period was negatively impacted by 940,260,104.38 CNY, contrasting with a positive increase of 691,671,145.49 CNY in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were RMB 12,863,222,727.13, an increase of 6.04% from the end of the previous year[5] - The total current assets as of March 31, 2022, amounted to RMB 8,868,108,412.42, up from RMB 8,122,784,414.33 at the end of December 2021, reflecting a growth of 9.2%[13] - The total liabilities increased to RMB 3,150,635,283.68 from RMB 2,999,987,775.25, representing a rise of 5.0%[15] - The company's equity attributable to shareholders rose to RMB 9,698,141,060.99 from RMB 9,116,878,404.95, reflecting an increase of 6.4%[15] Investments and Financial Assets - The company experienced a 109.25% increase in trading financial assets due to increased investments in financial products[8] - The net cash flow from investing activities was -1,945,146,440.65 CNY in Q1 2022, a substantial decline from -36,734,634.69 CNY in Q1 2021, reflecting increased investment expenditures[22] - Cash outflows from investing activities totaled 1,945,204,016.11 CNY in Q1 2022, compared to 821,420,318.95 CNY in Q1 2021, showing a rise of approximately 136%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 53,432[9] - Jiangsu Jichuan Holding Group Co., Ltd. held 46.92% of the shares, making it the largest shareholder[10] Other Income and Expenses - The company reported a significant increase in government subsidies, contributing to other operating income rising by 664.74%[8] - The company reported a significant increase in other income, which rose to approximately CNY 80.38 million from CNY 10.51 million, indicating a substantial growth in non-operating income[17] - Research and development expenses for the first quarter were approximately CNY 94.43 million, compared to CNY 78.53 million in the previous year, showing an increase of about 20.2%[17] - The tax expenses for the first quarter were approximately CNY 101.92 million, compared to CNY 66.11 million in the previous year, indicating an increase of about 54.1%[19] Accounting and Reporting - The company has not adopted the new accounting standards for the current year, which may affect future financial reporting and analysis[23] - The company has not disclosed any new product launches or technological advancements in the current report[12]